Today: 14 May 2026
Browse Category

Pharmaceuticals 25 January 2026 - 28 January 2026

Eli Lilly stock drops today: LLY slides after $1.12 billion gene-editing deal and Medicare pricing signal

Eli Lilly stock drops today: LLY slides after $1.12 billion gene-editing deal and Medicare pricing signal

Eli Lilly shares fell 2.4% to $1,015.05 Wednesday after the company announced a gene-editing deal with Seamless Therapeutics worth up to $1.12 billion. The U.S. government included Lilly’s Trulicity in the next round of Medicare drug-price negotiations, raising pricing concerns. Obesity drug rivals increased ad spending, intensifying competition.
28 January 2026
···
Pfizer stock dips after Xeljanz lands on Medicare price-talk list, with earnings looming

Pfizer stock dips after Xeljanz lands on Medicare price-talk list, with earnings looming

Pfizer shares fell 1.7% to $26.06 after CMS selected its arthritis drug Xeljanz for Medicare price negotiations, with new prices set for 2028. Xeljanz accounted for about $1.01 billion in Medicare spending in the latest period. Investors await Pfizer’s Feb. 3 quarterly results and a Feb. 28 CMS deadline for drugmakers to sign participation agreements.
28 January 2026
···
GSK share price slips in London as Arexvy EU expansion sinks in; earnings next week in focus

GSK share price slips in London as Arexvy EU expansion sinks in; earnings next week in focus

GSK shares dropped 1.8% to 1,828.5 pence by mid-morning Wednesday in London, reversing gains from earlier in the week. The decline followed news that the European Commission expanded approval of GSK’s RSV vaccine Arexvy to all adults 18 and older. Pfizer also secured similar approval for its RSV shot. Investors await guidance from European health agencies and GSK’s earnings report on February 4.
28 January 2026
···
Why Gilead stock hit a fresh 52-week high as Medicare targets Biktarvy and earnings loom

Why Gilead stock hit a fresh 52-week high as Medicare targets Biktarvy and earnings loom

Gilead Sciences shares rose 2.3% to $140.97 Tuesday, hitting a 52-week high after Medicare named its HIV drug Biktarvy for price negotiations starting in 2028. Trading volume topped 10.5 million shares. CEO Daniel O’Day sold 115,640 shares last week under a pre-set plan. Gilead will report fourth-quarter and full-year results after markets close on Feb. 10.
28 January 2026
···
Johnson & Johnson stock climbs after fresh FDA Darzalex Faspro nod — what investors watch next

Johnson & Johnson stock climbs after fresh FDA Darzalex Faspro nod — what investors watch next

Johnson & Johnson shares rose 1.3% Tuesday after the FDA approved a Darzalex Faspro combination for newly diagnosed multiple myeloma patients ineligible for stem-cell transplants. The S&P 500 closed at a record high, while healthcare stocks broadly fell after a Medicare payment proposal. The U.S. also named 15 drugs for future Medicare price negotiations, increasing pressure on big pharma.
28 January 2026
···
Eli Lilly stock price falls over 2% as Medicare puts Trulicity on 2028 price-talk list

Eli Lilly stock price falls over 2% as Medicare puts Trulicity on 2028 price-talk list

Eli Lilly shares closed down 2.3% at $1,039.51 Tuesday, then rose 0.3% after hours. U.S. Medicare officials named Lilly’s Trulicity among 15 drugs for 2028 price negotiations. The stock has dropped three straight sessions and now trades about 8% below its Jan. 8 peak. Investors await Lilly’s Feb. 4 earnings for updates on diabetes and obesity drug trends.
28 January 2026
·······
Eli Lilly stock edges up as Roche obesity-drug data keeps weight-loss race in view

Eli Lilly stock edges up as Roche obesity-drug data keeps weight-loss race in view

Eli Lilly shares rose 0.4% to $1,067.38 Tuesday, outperforming a weaker health-care sector as investors awaited the company’s Feb. 4 results. Roche reported its experimental obesity drug CT-388 achieved up to 22.5% placebo-adjusted weight loss in a Phase II trial and plans two Phase III studies this quarter. Novo Nordisk shares slipped. Investors remain focused on demand and supply for Lilly’s weight-loss drugs.
27 January 2026
·
AbbVie stock price closes higher; what to watch next for ABBV ahead of Fed week and earnings

AbbVie stock price closes higher; what to watch next for ABBV ahead of Fed week and earnings

AbbVie shares closed up 0.7% at $220.77 on Monday, moving with broader Wall Street gains ahead of the Federal Reserve’s policy decision and major tech earnings. The company will report full-year and Q4 results before the market opens on Feb. 4. AbbVie recently signed a $650 million cancer drug licensing deal with RemeGen and faces investor scrutiny over its post-Humira growth strategy.
27 January 2026
···
Gilead stock ticks up after BMO lifts target to $150, flags Yeztugo coverage gains

Gilead stock ticks up after BMO lifts target to $150, flags Yeztugo coverage gains

Gilead Sciences shares rose 0.9% to $137.21 midday Monday after BMO Capital Markets raised its price target to $150, citing expanded insurance coverage for Yeztugo, Gilead’s new HIV prevention shot. CVS confirmed coverage starting Jan. 1, pushing overall insurer coverage above 80%. Gilead says it has already met its 2025 Yeztugo sales target of $150 million. Investors await Gilead’s earnings report, expected Feb. 10.
26 January 2026
·
Eli Lilly stock slips in late morning trade as investors size up earnings and the obesity-pill race

Eli Lilly stock slips in late morning trade as investors size up earnings and the obesity-pill race

Eli Lilly shares slipped 0.1% to $1,062.87 in late morning trading Monday, extending last week’s decline. Investors are focused on the Feb. 4 earnings release and updates on obesity drug launches amid rising competition from Novo Nordisk. Early U.S. sales of Novo’s oral Wegovy and anticipation for Lilly’s orforglipron pill are drawing analyst attention. Legal and pricing pressures add uncertainty as both firms battle for market share.
26 January 2026
···
Sarepta Therapeutics (SRPT) stock jumps premarket ahead of Elevidys EMBARK 3-year data

Sarepta Therapeutics (SRPT) stock jumps premarket ahead of Elevidys EMBARK 3-year data

Sarepta Therapeutics shares rose 6.5% to $22.51 in early premarket trading Monday, following a 9.65% after-hours surge Friday ahead of new Elevidys trial data. Investors await three-year results from the Phase 3 EMBARK study in Duchenne muscular dystrophy, with safety concerns heightened after FDA restrictions and patient deaths. About 17,600 shares changed hands premarket, according to Public.com.
26 January 2026
·
Healthcare stocks brace for a key week: XLV slips as Wegovy pill data and UnitedHealth earnings loom

Healthcare stocks brace for a key week: XLV slips as Wegovy pill data and UnitedHealth earnings loom

The Health Care Select Sector SPDR Fund (XLV) fell 0.5% to $157.48 Friday, with Eli Lilly down 2.1%. Johnson & Johnson and UnitedHealth posted small gains. Traders are watching obesity-drug demand and a crowded earnings calendar next week. The FDA linked ByHeart’s recalled infant formula to a multi-state botulism outbreak.
25 January 2026
·····
Roche stock hovers near a 52-week high as investors brace for Thursday’s results

Roche stock hovers near a 52-week high as investors brace for Thursday’s results

Roche participation shares closed Friday at 348.10 Swiss francs, up 0.06% and near a 52-week high. The company will report full-year 2025 results before the Swiss market opens on Jan. 29, followed by a management webcast. Investors are watching for 2026 guidance and updates on drug launches and diagnostics demand. The Swiss Market Index fell 0.61% Friday.
25 January 2026
···
1 … 9 10 11 12 13 … 40

Stock Market Today

  • Vilas Transcore Shows Strong Earnings Growth and Insider Confidence
    May 13, 2026, 9:54 PM EDT. Vilas Transcore (NSE:VILAS) has demonstrated 20% compound annual growth in earnings per share (EPS) over three years, alongside revenue growth and a 3.3 percentage point increase in EBIT margin to 13%. The company's ₹9.9 billion market capitalization categorizes it as a small-cap stock, warranting attention to its financial health. Notably, insiders hold 73% ownership, aligning management's interests with shareholders. These factors suggest Vilas Transcore could offer stable returns for investors seeking profitable, growing firms. However, potential investors should conduct further due diligence before adding it to their watchlists.

Latest articles

Enovix Stock Drops After Q1 Beat as Smartphone Battery Tests Stay Unfinished

Enovix Stock Drops After Q1 Beat as Smartphone Battery Tests Stay Unfinished

14 May 2026
Enovix shares dropped 12.9% to $6.35 after hours Wednesday despite beating first-quarter revenue and adjusted-loss estimates. The decline followed news that smartphone battery qualification remains unfinished, with the company passing 72 of 75 customer tests. Revenue rose 49% to $7.6 million. Enovix cited progress in defense, industrial, and smart-eyewear sales.
Lightwave Logic Stock Jumps as AI-Photonics Bet Heads for a 2027 Production Test

Lightwave Logic Stock Jumps as AI-Photonics Bet Heads for a 2027 Production Test

14 May 2026
Lightwave Logic reported Q1 revenue up 27% to $29,000 and a net loss widening to $6.3 million. Shares rose 14% after the company said it is negotiating a supply and licensing deal for high-volume production in 2027. Four Fortune 500 customers are now in Stage 3 prototyping. Cash and equivalents totaled about $100 million as of May 11.
USA Rare Earth Stock Watch: Q1 Revenue, $1.75 Billion Cash and the China Supply Crunch

USA Rare Earth Stock Watch: Q1 Revenue, $1.75 Billion Cash and the China Supply Crunch

14 May 2026
USA Rare Earth reported Q1 revenue of $5.7 million and a net loss of $67 million, ending March with $1.75 billion in cash after a $1.5 billion PIPE. The company expects to sign documents this month for $1.6 billion in U.S. Commerce Department funding. Texas awarded a $14.18 million grant for the Round Top project. USA Rare Earth agreed in April to acquire Brazil’s Serra Verde for $2.8 billion.
Go toTop